Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
A live, multi-source view of Bio-Rad Laboratories, Inc. (BIO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software.
Sector: Healthcare · Industry: Medical Devices · United States · 7,450 employees · bio-rad.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Bio-Rad Laboratories, Inc. (BIO) had a market capitalization of $10.32B, a trailing P/E of 47.1 (forward 38.5) and a beta of 1.07; the shares traded in a 52-week range of $236.73 – $396.23 (33.6% over the year).
- Market cap
- $10.32B
- Enterprise value
- $10.08B
- Trailing P/E
- 47.1
- Forward P/E
- 38.5
- PEG ratio
- 4.01
- Price / book
- 1.44
- EPS (trailing)
- $8.19
- EPS (forward)
- $10.03
- Payout ratio
- 0.0%
- 52-week range
- $236.73 – $396.23
- 52-week change
- 33.6%
- Beta
- 1.07
- Average volume
- 301,370
- Shares outstanding
- 21.7M
- Short % of float
- 0.00%
- Profit margin
- 8.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Bio-Rad Laboratories, Inc. (BIO) last closed at $386.11 (the last completed close before that scan).
Technicals at the scan: RSI 69 (neutral territory), price +3.1% versus its 20-day average, 20-day versus 50-day average spread +11.3%, MACD histogram -1.28.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 50/100.
Next scheduled company event: in 51 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for BIO in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
BIO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Bio-Rad Laboratories, Inc. (BIO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell BIO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.